Genscript Biotech Corporation
GNNSF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.83B
Close$
$-4.68
204.1% downside
Current Fair Value
204.1% downsideOvervalued by 204.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $9.83 Billion |
|---|---|
| Enterprise Value | $10.02 Billion |
| Earnings per Share | $-0.25 |
| Beta | 0.85 |
| Outstanding Shares | 2,185,337,993 |
Return
| Return on Equity | 63.70% |
|---|---|
| Return on Assets | 51.70% |
| Return on Invested Capital | 11.45% |
Valuation & Multiples
| P/E Ratio | -14.95 |
|---|---|
| PEG | -3.68 |
| Price to Sales | - |
| Price to Book Ratio | 4.5 |
| Enterprise Value to Revenue | 7.18 |
| Enterprise Value to EBIT | 21.56 |
| Enterprise Value to Net Income | 4 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 16, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$383.94 M
Consensus analyst estimateNext Earnings Call
Expected Date
March 24, 2027
EPS Estimate
$0.01
Consensus analyst estimateRevenue Estimate
$495.80 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Genscript Biotech Corporation
6,135 employees
CEO: Weihui Shao
Operating as an investment holding company, Genscript Biotech Corporation, established in 2002 and headquartered in Nanjing, People's Republic of China, specializes in the global provision of innovative life science research solutions, e...